Large Scale Ranking and Repositioning of Drugs with Respect to DrugBank Therapeutic Categories

The ranking and prediction of novel therapeutic categories for existing drugs (drug repositioning) is a challenging computational problem involving the analysis of complex chemical and biological networks. In this context we propose a novel semi-supervised learning problem: ranking drugs in integrated bio-chemical networks according to specific DrugBank therapeutic categories. To deal with this challenging problem, we designed a general framework based on bipartite network projections by which homogeneous pharmacological networks can be combined and integrated from heterogeneous and complementary sources of chemical, biomolecular and clinical information. Moreover, we propose a novel method based on kernelized score functions for fast and effective drug ranking in the integrated pharmacological space. Results with 51 therapeutic DrugBank categories involving about 1300 FDA approved drugs show the effectiveness of the proposed approach.

[1]  Alexander J. Smola,et al.  Kernels and Regularization on Graphs , 2003, COLT.

[2]  Bernhard Schölkopf,et al.  Learning Theory and Kernel Machines , 2003, Lecture Notes in Computer Science.

[3]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[4]  Yoshihiro Yamanishi,et al.  Drug-target interaction prediction from chemical, genomic and pharmacological data in an integrated framework , 2010, Bioinform..

[5]  Li Gong,et al.  PharmGKB: An Integrated Resource of Pharmacogenomic Data and Knowledge , 2008, Current protocols in bioinformatics.

[6]  Bernhard Schölkopf,et al.  Computational Learning Theory and Kernel Machines, 16th Annual Conference on Computational Learning Theory and 7th Kernel Workshop, COLT/Kernel 2003, Washington, DC, USA, August 24-27, 2003, Proceedings , 2003, Annual Conference Computational Learning Theory.

[7]  Zoubin Ghahramani,et al.  Gene function prediction from synthetic lethality networks via ranking on demand , 2010, Bioinform..

[8]  T. Golub,et al.  Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. , 2006, Cancer cell.

[9]  L. Asz.  Random Walks on Graphs: a Survey , 2022 .

[10]  N. Nikolova,et al.  International Union of Pure and Applied Chemistry, LUMO energy ± The Lowest Unoccupied Molecular Orbital (LUMO) , 2022 .

[11]  J. DiMasi.  New drug development in the United States from 1963 to 1999 , 2001, Clinical pharmacology and therapeutics.

[12]  Xiaoyan Zhu,et al.  Building Disease-Specific Drug-Protein Connectivity Maps from Molecular Interaction Networks and PubMed Abstracts , 2009, PLoS Comput. Biol..

[13]  Damian Szklarczyk,et al.  STITCH 2: an interaction network database for small molecules and proteins , 2009, Nucleic Acids Res..

[14]  Michael J. Keiser,et al.  Predicting new molecular targets for known drugs , 2009, Nature.

[15]  Thomas C. Wiegers,et al.  The Comparative Toxicogenomics Database: update 2011 , 2010, Nucleic Acids Res..

[16]  A. Chiang,et al.  Systematic Evaluation of Drug–Disease Relationships to Identify Leads for Novel Drug Uses , 2009, Clinical pharmacology and therapeutics.

[17]  G. Schneider,et al.  Predicting Compound Selectivity by Self‐Organizing Maps: Cross‐Activities of Metabotropic Glutamate Receptor Antagonists , 2006, ChemMedChem.

[18]  Christian von Mering,et al.  STITCH: interaction networks of chemicals and proteins , 2007, Nucleic Acids Res..

[19]  Anton Yuryev,et al.  Computational Approaches for Drug Repositioning and Combination Therapy Design , 2010, J. Bioinform. Comput. Biol..

[20]  Susan M Hanson,et al.  Structural Mechanisms Underlying Benzodiazepine Modulation of the GABAA Receptor , 2008, The Journal of Neuroscience.

[21]  Thomas C. Wiegers,et al.  The Comparative Toxicogenomics Database: update 2013 , 2012, Nucleic Acids Res..

[22]  T. Ashburn,et al.  Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.

[23]  J. Barker,et al.  Benzodiazepines specifically modulate GABA-mediated postsynaptic inhibition in cultured mammalian neurones , 1978, Nature.

[24]  Peter M Woollard,et al.  The application of next-generation sequencing technologies to drug discovery and development. , 2011, Drug discovery today.

[25]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[26]  R. Tagliaferri,et al.  Discovery of drug mode of action and drug repositioning from transcriptional responses , 2010, Proceedings of the National Academy of Sciences.

[27]  Alexander A. Morgan,et al.  Discovery and Preclinical Validation of Drug Indications Using Compendia of Public Gene Expression Data , 2011, Science Translational Medicine.

[28]  Encoding Rules,et al.  SMILES, a Chemical Language and Information System. 1. Introduction to Methodology , 1988 .

[29]  Geeta Anand,et al.  How drug's rebirth as treatment for cancer fueled price rises. , 2004, Wall Street journal.

[30]  R Sandyk,et al.  L-tryptophan supplementation in Parkinson's disease. , 1989, The International journal of neuroscience.

[31]  David S. Wishart,et al.  DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs , 2010, Nucleic Acids Res..

[32]  P. Bork,et al.  A side effect resource to capture phenotypic effects of drugs , 2010, Molecular systems biology.

[33]  R. Sharan,et al.  PREDICT: a method for inferring novel drug indications with application to personalized medicine , 2011, Molecular systems biology.

[34]  Joel Dudley,et al.  Exploiting drug-disease relationships for computational drug repositioning , 2011, Briefings Bioinform..

[35]  Lincoln Stein,et al.  Reactome: a database of reactions, pathways and biological processes , 2010, Nucleic Acids Res..